| 6.12 -0.13 (-2.08%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.57 |
1-year : | 11.21 |
| Resists | First : | 8.19 |
Second : | 9.6 |
| Pivot price | 7.22 |
|||
| Supports | First : | 5.92 |
Second : | 4.92 |
| MAs | MA(5) : | 6.29 |
MA(20) : | 7.47 |
| MA(100) : | 7.93  |
MA(250) : | 5.18 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 7.1 |
| RSI | RSI(14): 25.4 |
|||
| 52-week | High : | 11.67 | Low : | 2.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EPIX ] has closed above bottom band by 14.9%. Bollinger Bands are 31.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.44 - 6.49 | 6.49 - 6.52 |
| Low: | 5.82 - 5.87 | 5.87 - 5.91 |
| Close: | 6.05 - 6.13 | 6.13 - 6.19 |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Tue, 16 Apr 2024
Hedge funds investors in ESSA Pharma Inc. (NASDAQ:EPIX) lost 12% last week but have reaped the benefits of longer ... - Simply Wall St
Sun, 14 Apr 2024
ESSA Pharma Inc. (NASDAQ:EPIX) Short Interest Update - MarketBeat
Sat, 13 Apr 2024
ESSA Pharma (NASDAQ:EPIX) Share Price Crosses Below Fifty Day Moving Average of $8.94 - MarketBeat
Wed, 14 Feb 2024
ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results - Yahoo Finance
Wed, 07 Feb 2024
ESSA Pharma Inc Executive Peter Virsik Sells 72,782 Shares - Yahoo Finance
Mon, 22 Jan 2024
ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 78.7 (%) |
| Shares Short | 803 (K) |
| Shares Short P.Month | 979 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -17.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -10.38 |
| PEG Ratio | 0 |
| Price to Book value | 1.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|